European Union - English - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - hexyon (dtap-ipv-hb-hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

Malta - English - Medicines Authority

bilthoven biologicals b.v. antonie van leeuwenhoeklaan 9 3721 ma, bilthoven, netherlands - suspension for injection - poliovirus (inactivated) type 3 (saukett strain) 7.5 dagu diphtheria toxoid >5 iu tetanus toxoid >20 iu poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 4 dagu - vaccines

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria antitoxin 10000 [iu] - solution for injection - 10000 iu - active: diphtheria antitoxin 10000 [iu] excipient: hydrochloric acid phenol sodium chloride sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - diphtheria antitoxin 2000 iu/ml - solution for injection - 2000 iu/ml - active: diphtheria antitoxin 2000 iu/ml excipient: phenol

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - diphtheria antitoxin 4000 iu/ml - solution for injection - 4000 iu/ml - active: diphtheria antitoxin 4000 iu/ml excipient: phenol

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 2 [iu] - solution for injection - 2 iu/0.5ml - active: diphtheria toxoid, adsorbed 2 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride thiomersal

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 30 [iu] - solution for injection - 30 iu/0.5ml - active: diphtheria toxoid, adsorbed 30 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate monohydrate sodium chloride thiomersal

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =); haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)); diphtheria toxoid, adsorbed 30 [iu] (> or =); pertactin 8ug; pertussis filamentous haemagglutinin 25ug; pertussis toxoid, adsorbed 25ug; tetanus toxoid 40 [iu] (> or =) - suspension for injection - active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide sodium chloride water for injection active: haemophilus influenzae vaccine, tetanus toxoid conjugate 10ug (as prp (target fill 10mcg + 2.5mcg overage)) excipient: lactose monohydrate sodium chloride water active: diphtheria toxoid, adsorbed 30 [iu] (> or =) pertactin 8ug pertussis filamentous haemagglutinin 25ug pertussis toxoid, adsorbed 25ug tetanus toxoid 40 [iu] (> or =) excipient: aluminium hydroxide phenoxyethanol sodium chloride water for injection - infanrixtm-hib is indicated for active immunisation against diphtheria, tetanus, pertussis (dtp) and haemophilus influenzae type b (hib) infection in all children from 15 months of age.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - neisseria meningitidis c; tetanus toxoid - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - meningococcal vaccines - meningococcal vaccine - it is indicated for active immunisation in children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.